Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

Fort Collins, Colorado, Dec. 07, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, The CRISPR Technology Market is expected to value USD 3.2 Billion in 2022 and is projected to reach USD 12 ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold 395,617 shares of CRISPR Therapeutics AG during the third quarter. Its ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Cathie Wood's ARK Invest bought $17M in CRISPR and Beam gene-editing stocks while selling Teradyne, Roku, and SoFi shares on ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...